| Today's Big NewsSep 27, 2022 |
Black, Hispanic patients are neglected by 'one size fits all' MS trials. Genentech aims to change that FDA slaps partial hold on Avidity's lead program, docking dystrophy study over serious adverse event Months after an executive exodus, Exicure tells 66% of remaining staff to exit as it suspends all R&D work Genentech pays $70M to access Arsenal's armory of T-cell tools in quest for solid tumor CAR-T Sanofi pays Scribe $25M to access CRISPR tools, writing new chapter in its NK cell therapy story Biogen finalizes $900M deal to settle whistleblower’s long-running MS kickback suit MIT 'human radar' device tracks movement, gait speed of Parkinson's patients at home InterWell Health continues kidney care expansion with acquisition of Acumen Physician Solutions Emergent wraps up purchase of Chimerix's potential monkeypox treatment Tembexa HHS expands ownership data set for 15,000 Medicare-certified nursing homes MHRA raises concerns with switching between long-acting J&J, Novartis and Takeda drugs |
| By Gabrielle Masson Genentech is focused on building more equitable healthcare for Black and Hispanic multiple sclerosis communities while moving away from a “one size fits all” treatment approach, said Ashish Pradhan, M.D., executive director and disease area lead for MS. |
|
|
|
By Nick Paul Taylor Avidity Biosciences’ lead program has hit choppy waters. The FDA has put the phase 1/2 MARINA clinical trial of RNA therapeutic AOC 1001 on partial hold in response to a serious adverse event in one patient. |
Sponsored By THREAD One aspect of study design to consider when building better research experiences for patients is a genuinely patient-centered eCOA (electronic clinical outcome assessment) program. Here are some tips for ensuring that your eCOA is built with the needs of patients in mind and able to deliver the kind of engagement necessary for successful trials. |
Sponsored By Agilex Biolabs Australia’s largest and most technologically advanced provider of regulated bioanalysis and toxicology studies increases capacity by 500% with addition of new in-vivo facility in Brisbane |
By Max Bayer Exicure can't seem to shake off a nearly yearlong rut, cutting two-thirds of its staff less than a year after laying off half the team. The company appears to be on its last legs, saying it will also be halting all R&D work. |
By James Waldron In the race to create a CAR-T therapy that can treat solid tumors, Genentech has decided it needs all the help it can get. The Roche unit has fronted $70 million to use Arsenal Biosciences’ armory of screening and T-cell engineering tools to find a truly successful target. |
By Nick Paul Taylor Sanofi has teamed up with Scribe Therapeutics to write the next chapter in its natural killer (NK) cell therapy story, paying $25 million upfront and committing to $1 billion in biobucks for access to a CRISPR platform. |
By Angus Liu Years into a whistleblower suit that alleged illegal kickbacks to physicians, Biogen is now finally able to end the legal saga just as it gears up for an imminent Alzheimer's readout. |
By Andrea Park Radar technology is used to track vehicles, measure driving speeds, forecast weather changes and, now, to remotely monitor the severity and progression of Parkinson’s disease. |
By Paige Minemyer InterWell Health is further expanding its kidney care services with the addition of Acumen Physician Solutions, the company announced Tuesday. |
By Kevin Dunleavy Emergent BioSolutions has completed its acquisition of smallpox oral antiviral Tembexa. The deal with North Carolina-based Chimerix for worldwide rights to the drug calls for an upfront fee of $238 million, with milestone payments of up to $124 million contingent on the U.S. exercising supply options. Tembexa is another potential tool to combat monkeypox. |
By Dave Muoio The expanded data on roughly 15,000 nursing homes show which facilities are under common ownership so researchers and regulators can better identify any connections to poor care quality, HHS said Monday. |
By Nick Paul Taylor The U.K. drug regulator has told healthcare professionals to exercise caution when considering switching between long-acting attention-deficit/hyperactivity disorder therapies from companies including Johnson & Johnson, Novartis and Takeda. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we'll discuss how two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. We'll discuss their strategies and what we can expect for the future. |
|
|---|
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
Multimedia ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation Sponsored by: ZS |
| |
|
